Sequencing therapy for advanced renal cancer
- PMID: 31810798
- DOI: 10.1016/S1470-2045(19)30781-8
Sequencing therapy for advanced renal cancer
Comment on
-
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.Lancet Oncol. 2020 Jan;21(1):95-104. doi: 10.1016/S1470-2045(19)30735-1. Epub 2019 Dec 3. Lancet Oncol. 2020. PMID: 31810797 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical